Wilms' tumor: A paradigm for the new genetics

Oncology Research

Volumn 12, Issue 11-12, 2000, Pages 441-449

  Malik, Karim ^a   Yan, Pearlly ^b   Huang, Tim H M ^b   Brown, Keith W ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b University of Missouri   (United States)

Author keywords

Epigenetics; Genomics; Tumor suppressor genes; Wilms' tumor; WT1

Indexed keywords

WT1 PROTEIN;

BIOLOGICAL MODEL; GENETICS; HUMAN; KIDNEY TUMOR; NEPHROBLASTOMA; REVIEW; TUMOR SUPPRESSOR GENE;

GENES, WILMS TUMOR; HUMANS; KIDNEY NEOPLASMS; MODELS, GENETIC; WILMS TUMOR; WT1 PROTEINS;

EID: 0034584526     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504001108747440     Document Type: Review

References (81)

1. Coppes, M. J.; Campbell, C. E.; Williams, B. R. G. Wilms' tumour. Clinical and molecular characterisation. Austin, TX: R. G. Landes Company; 1995.
2. Ekblom, P. Renal development. In: Seldin, D. W.; Giebisch, G., eds. The kidney: Physiology and pathophysiology (2nd ed.). New York: Raven Press; 1991:475-501.
3. Koseki, C.; Herzlinger, D.; Alawqati, Q. Apoptosis in metanephric development. J. Cell. Biol. 119:1327-1333; 1992.
4. Van Heyningen, V.; Hastie, N. D. Wilms' tumour: Reconciling the genetics and biology. Trends Genet. 8:16-21; 1992.
5. Beckwith, J. B.; Kiviat, N. B.; Bonadio, J. F. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumour. Paediatr. Pathol. 10:1-36; 1990.
6. Knudson, A. G.; Strong, L. C. Mutation and cancer. A model for Wilms' tumour of the kidney. J. Natl. Cancer Inst. 48:313-324; 1972.
7. Franke, U.; Holmes, L. B.; Atkins, L.; Riccardi, V. M. Aniridia Wilms' tumour association: Evidence for specific deletion of 11p13. Cytogenet. Cell. Genet. 24:185-192; 1979.
8. Reik, W.; Maher, E. R. Imprinting in clusters: Lessons from Beckwith-Wiedemann Syndrome. Trends Genet. 13:330-334; 1997.
9. Coppes, M. J.; Campbell, C. E.; Williams, B. R. G. The role of WT1 in Wilms' tumourigenesis. FASEB J. 7:886-895; 1993.
10. Park, S.; Bernard, A.; Bove, K. E.; Sens, D. A.; Hazen-Martin, D. J.; Garvin, A. J.; Haber, D. A. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour. Nat. Genet. 5: 363-367; 1993.
11. Hastie, N. D. Dominant negative mutations in the Wilms' tumour (WT1) gene cause Denys-Drash Syndrome - proof that a tumour suppressor gene plays a crucial role in normal genitourinary development. Hum. Mol. Genet. 1:293-295; 1992.
12. Pritchard Jones, K.; Fleming, S.; Davidson, D.; Bickmore, W.; Porteous, D.; Gosden, C.; Bard, J.; Buckler, A.; Pelletier, J.; Housman, D. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 346:194-197; 1990.
13. Hosono, S.; Luo, X.; Hyink, D. P.; Schnapp, L. M.; Wilson, P. D.; Burrow, C. R.; Reddy, J. C.; Atweh, G. F.; Licht, J. D. WT1 expression induces features of renal epithelial differentiation in mesenchymal fibroblasts. Oncogene 18:417-427; 1999.
14. Englert, C.; Hou, X.; Maheswaran, S.; Bennett, P.; Ngwu, C.; Re, G. G.; Garvin, A. J.; Rosner, M. R.; Haber, D. A. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J. 14:4662-4675; 1995.
15. Kreidberg, J. A.; Sariola, H.; Loring, J. M.; Maeda, M.; Pelletier, J.; Housman, D.; Jaenisch, R. WT-1 is required for early kidney development Cell 74:679-691; 1993.
16. Haber, D. A.; Sohn, R. L.; Buckler, A. J.; Pelletier, J.; Call, K. M.; Housman, D. E. Alternative splicing and genomic structure of the Wilms' tumour gene WT1. Proc. Natl. Acad. Sci. USA 88: 9618-9622; 1991.
17. Sharma, P. M.; Bowman, M.; Madden, S. L.; Rauscher, F. J.; Sukumar, S. RNA editing in the Wilms' tumour susceptibility gene, WT1. Gene Dev. 8:720-731; 1994.
18. Bruening, W.; Pelletier, J. A non-aug translational initiation event generates novel WT1 isoforms. J. Biol. Chem. 271:8646-8654; 1996.
19. Little, M.; Holmes, G.; Walsh P. WT1: What has the last decade told us? Bioessays 21:191-202; 1999.
20. Lee, S. B.; Huang, K.; Palmer, R.; Truong, V. B.; Herzlinger, D.; Kolquist, K. A.; Wong, J.; Paulding, C.; Yoon, S. K.; Gerald, W.; Oliner, J. D.; Haber, D. A. The Wilms' tumour suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell 98:663-673; 1999.
21. Mayo, M. W.; Wang, C.-Y.; Drouin, S. S.; Madrid, L. V.; Marshall, A. F.; Reed, J. C.; Weissman, B. E.; Baldwin, A. S. WT1 modulates apoptosis by transcriptionally upregulating the Bc1-2 proto-oncogene. EMBO J. 18:3990-4003; 1999.
22. Schroeder, W. T.; Chao, L. Y.; Dao, D. D.; Strong, L. C.; Pathak, S.; Riccardi, V.; Lewis, W. H.; Saunders, G. F. Nonrandom loss of maternal chromosome 11 alleles in Wilms' tumours. Am. J. Hum. Genet 40:413-420; 1987.
23. Reik, W.; Surani, A. Genomic imprinting and embryonal tumours. Nature 338:112-113; 1989.
24. Huang, A.; Campbell, C. E.; Bonetta, L.; McAndrews Hill, M. S.; Chilton MacNeill, S.; Coppes, M. J.; Law, D. J.; Feinberg, A. P.; Yeger, H.; Williams, B. R. Tissue, developmental, and tumour-specific expression of divergent transcripts in Wilms tumour. Science 250:991-994; 1990.
25. Campbell, C. E.; Huang, A.; Gurney, A. L.; Kessler, P. M.; Hewitt, J. A.; Williams, B. R. G. Antisense transcripts and protein binding motifs within the Wilms' tumour (WT1) locus. Oncogene 9:583-595; 1994.
26. Eccles, M. R.; Grubb, G.; Ogawa, O.; Szeto, J.; Reeve, A. E. Cloning of novel Wilms' tumour gene (WT1) cDNAs; evidence for antisense transcription of WT1. Oncogene 9:2059-2063; 1994.
27. Tilghman, S. M. The sins of the fathers and mothers: Genomic imprinting in mammalian development. Cell 96:185-193; 1999.
28. Joyce, J. A.; Schofield, P. N. Genomic imprinting and cancer. J. Clin. Pathol. Mol. Pathol. 51:185-190; 1998.
29. Feil, R.; Khosla, S. Genomic imprinting in mammals: An interplay between chromatin and DNA methylation? Trends Genet. 15:431-435; 1999.
30. Sleutels, F.; Barlow, D. P.; Lyle, R. The uniqueness of the imprinting mechanism. Curr. Opin. Genet. Dev. 10:229-233; 2000.
31. Malik, K.; Salpekar, A.; Hancock, A.; Moorwood, K.; Jackson, S.; Charles, A.; Brown, K. W. Identification of differential methylation of the WT1 antisense regulatory region and relaxation of imprinting in Wilms' tumour. Cancer Res. 60:2356-2360; 2000.
32. Moorwood, K.; Charles, A. K.; Salpekar, A.; Wallace, J. I.; Brown, K. W.; Malik, K. Antisense WT1 transcription parallels sense mRNA and protein expression in foetal kidney and can elevate protein levels in vitro. J. Pathol. 185:352-359; 1998.
33. Reeve, A. E.; Sih, S. A.; Raizis, A. M.; Feinberg, A. P. Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumour cells. Mol. Cell. Biol. 9:1799-1803; 1989.
34. Maher, E. R.; Reik, W. Beckwith-Wiedemann syndrome: Imprinting in clusters revisited. J. Clin. Invest. 105:247-252; 2000.
35. Feinberg, A. P. Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: An introduction. Cancer Res. 59: 1743s-1746s; 1999.
36. Moulton, T.; Crenshaw, T.; Hao, Y.; Moosikasuwan, J.; Lin, N.; Dembitzer, F.; Hensle, T.; Weiss, L.; McMorrow, L.; Loew, T.; Kraus, W.; Gerald, W.; Tycko, B. Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat. Genet 7:440-447; 1994.
37. Cui, H.; Hedborg, F.; He, L.; Nordenskjold, A.; Sandstedt, B.; Pfeifer-Ohlsson, S.; Ohlsson, R. Inactivation of H19, an imprinted and putative tumour represser gene, is a preneoplastic event during Wilms' tumourigenesis. Cancer Res. 57:4469-4473; 1997.
38. Hao, Y.; Crenshaw, T.; Moulton, T.; Newcomb, E.; Tycko B. Tumour-suppressor activity of H19 RNA. Nature 365:764-767; 1993.
39. Steenman, M. J. C.; Rainer, S.; Dobry, C. J.; Grundy, P.; Horon, I. L.; Feinberg, A. P. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat. Genet 7:433-439; 1994.
40. Bell, A. C.; Felsenfeld, G. Methylation of a CTCF-dependent boundary controls imprinted expression of the IGF2 gene. Nature 405:482-485; 2000.
41. Hark, A. T.; Schoenherr, C. J.; Katz, D. J.; Ingram, R. S.; Levorse, J. M.; Tilghman, S. M. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/IGF2 locus. Nature 405:486-489; 2000.
42. Baccarini, P.; Fiorentino, M.; D'Errico, A.; Mancini, A. M.; Grigioni W. F. Detection of anti-sense transcripts of the insulin-like growth factor-2 gene in Wilms' tumour. Am. J. Pathol. 143:1535-1542; 1993.
43. Okutsu, T.; Kuroiwa, Y.; Kagitani, F.; Kai, M.; Aisaka, K.; Tsutsumi, O.; Kaneko, Y.; Yokomori, K.; Surani, M. A.; Kohda, T.; Kaneko-Ishino, T.; Ishino, F. Expression and imprinting status of human PEG8/IGF2AS, a paternally expressed antisense transcript from the IGF2 locus, in Wilms' tumours. J. Biochem. 127:475-483; 2000.
44. Hastie, N. D. The genetics of Wilms' tumour - a case of disrupted development Annu. Rev. Genet. 28:523-558; 1994.
45. Grundy, P. E.; Telzerow, P. E.; Breslow, N.; Moksness, J.; Huff, V.; Paterson, M. C. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumours predicts an adverse outcome. Cancer Res. 54:2331-2333; 1994.
46. Charles, A. K.; Brown, K. W.; Berry, P. J. Microdissecting the genetic events in nephrogenic rests and Wilms' tumour development. Am. J. Pathol. 153:991-1000; 1998.
47. Radice, P.; Perotti, D.; Debenedetti, V.; Mondini, P.; Radice, M. T.; Pilotti, S.; Luksch, R.; Bellani, F. F.; Pierotti, M. A. Allelo-typing in Wilms' tumours identifies a putative third tumour suppressor gene on chromosome 11. Genomics 27:497-501; 1995.
48. Wilmore, H. P.; White, G. F. J.; Howell, R. T.; Brown, K. W. Germline and somatic abnormalities of chromosome 7 in Wilms' tumour. Cancer Genet. Cytogenet. 77:93-98; 1994.
49. Powlesland, R. M.; Charles, A. K.; Malik, K. T. A.; Reynolds, P. A.; Pires, S.; Boavida, M.; Brown, K. W. Loss of heterozygosity at 7p in Wilms' tumour development Br. J. Cancer 82:323-329; 2000.
50. Rahman, N.; Arbour, L.; Tonin, P.; Renshaw, J.; Pelletier, J.; Baruchel, S.; Pritchard-Jones, K.; Stratton, M. R.; Narod, S. A. Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12-q21. Nat. Genet. 13:461-463; 1996.
51. McDonald, J. M.; Douglass, E. C.; Fisher, R.; Geiser, C. F.; Krill, C. E.; Strong, L. C.; Virshup, D.; Huff, V. Linkage of familial Wilms' tumour predisposition to chromosome 19 and a two-locus model for the aetiology of familial tumours. Cancer Res. 58: 1387-1390; 1998.
52. Knudson, A. G. Paediatric molecular oncology-past as prologue to the future. Cancer 71:3320-3324; 1993.
53. Park, S.; Schalling, M.; Bernard, A.; Maheswaran, S.; Shipley, G. C.; Roberts, D.; Fletcher, J.; Shipman, R.; Rheinwalld, J.; Demetri, G.; Griffin, J.; Minden, M.; Housman, D. E.; Haber, D. A. The Wilms'-tumour gene WT1 is expressed in murine mesodermderived tissues and mutated in a human mesothelioma. Nat Genet 4:415-420; 1993.
54. Sekiya, M.; Adachi, M.; Hinoda, Y.; Imai, K.; Yachi, A. Downregulation of Wilms' tumour gene (WT1) during myelomonocytic differentiation in HL60 cells. Blood 83:1876-1882; 1994.
55. Phelan, S. A.; Lindberg, C.; Call, K. M. Wilms' tumour gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. Cell Growth Differ. 5:677-686; 1994.
56. Iinoue, K.; Ogawa, H.; Sonoda, Y.; Kimura, T.; Sakabe, H.; Oka, Y.; Miyake, S.; Tamaki, H.; Oji, Y.; Yamagami, T.; Tatekawa, T.; Soma, T.; Kishimoto, T.; Sugiyama, H. Aberrant overexpression of the Wilms' tumour gene (WT1) in human leukaemia. Blood 89:1405-1412; 1997.
57. King-Underwood, L.; Renshaw, J.; Pritchard-Jones, K. Mutations in the Wilms' tumour gene WT1 in leukaemias. Blood 87:2171-2179; 1996.
58. Silberstein, G. B.; Van Horn, K.; Strickland, P.; Roberts, C. T., Jr.; Daniel, C. W. Altered expression of the WT1 Wilms' tumour suppressor gene in human breast cancer. Proc. Natl. Acad. Sci. USA 94:8132-8137; 1997.
59. Hiltunen, M. O.; Koistinaho, J.; Alhonen, L.; Myöhänen, S.; Marin, S.; Kosma, V-M.; Pääkkänen, M.; Jänne, J. Hypermethyladon of the WT1 and calcitonin gene promoter regions at chromosome 11pp in human colorectal cancer. Br. J. Cancer 76:1124-1130; 1997.
60. Karnik, P.; Paris, M.; Williams, B. R. G.; Casey, G.; Crowe, J.; Chen, P. Two distinct tumour suppressor loci within chromosome 11p15 implicated in breast cancer progression and metastasis. Hum. Mol. Genet. 7:895-903; 1998.
61. Doucrasy, S.; Barrois, M.; Fogel, S.; Ahomadegbe, J. C.; Stehelin, D.; Coll, J.; Riou, G. High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and bialleic hypomethylation of H19. Oncogene 12:423-430; 1996.
62. Hodzic, D.; Frey, B.; Marechal, D.; Scarcez, T.; Grooteclaes, M.; Winkler, R. Cloning of breakpoints in and downstream the IGF2 gene that are associated with overexpression of IGF2 transcripts in colorectal tumours. Oncogene 18:4710-4717; 1999.
63. Kinouchi, Y.; Hiwatashi, N.; Higashioka, S.; Nagashima, F.; Chida, M.; Toyota, T. Relaxation of imprinting of the insulin-like growth factor II gene in colorectal cancer. Cancer Lett. 107: 105-108; 1996.
64. Cui, H.; Horon, I. L.; Ohlsson, R.; Hamilton, S. R.; Feinberg, A. P. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat. Med. 4:1276-1280; 1998.
65. Schwienbacher, C.; Angioni, A.; Scelfo, R.; Veronese, A.; Calin, G. A.; Massazza, G.; Hatada, I.; Barbanti-Brodano, G.; Negrini, M. Abnormal RNA expression of 11p15 imprinted genes and kidney developmental genes in Wilms' tumour. Cancer Res. 60: 1521-1525; 2000.
66. Yu, Y.; Xu, F.; Peng, H.; Fang, X.; Zhao, S.; Li, Y.; Cuevas, B.; Kuo, W-L.; Gray, J. W.; Siciliano, M.; Mills, G. B.; Bast, R. C., Jr. NOEY2 (ARHI), an imprinted putative tumour suppressor gene in ovarian and breast carcinomas. Proc. Natl. Acad. Sci. USA 96: 214-219; 1999.
67. Xu, F.; Xia, W.; Luo, R. Z.; Peng, H.; Zhao, S.; Dai, J.; Long, Y.; Zou, L.; Le, W.; Liu, J.; Parlow, A. F.; Hung, M.; Bast, R. C.; Yu, Y. The human ARHI tumour suppressor gene inhibits lactation and growth in transgenic mice. Cancer Res. 60:4913-4920; 2000.
68. Mai, M.; Qian, C.; Yokomizo, A.; Tindall, D. J.; Bostwick, D.; Polychronakos, C.; Smith, D. I.; Liu, W. Loss of imprinting and allele switching of p73 in renal cell carcinoma. Oncogene 17: 1739-1741; 1998.
69. Baylin, S. B.; Herman, J. G. DNA hypermethylation in tumourigenesis. Trends Genet. 16:168-174; 2000.
70. Zhang, Y. H.; Shields, T.; Crenshaw, T.; Hao, Y.; Moulton, T.; Tycko, B. Imprinting of human H19: Allele-specific CpG methylation, loss of the active allele in Wilms' tumour and potential for somatic allele switching. Am. J. Hum. Genet 53:113-124; 1993.
71. Brannan, C. I.; Dees, E. C.; Ingram, R. S.; Tilghman, S. M. The product of the H19 gene may function as an RNA. Mol. Cell. Biol. 10:28-36; 1990.
72. Haselbacher, G. K.; Irminger, J-C.; Zapf, J.; Ziegler, W. H.; Humbel, R. E. Insulin-like growth factor II in human adrenal pheochromocytomas and Wilms' tumours: Expression at the mRNA and protein level. Proc. Natl. Acad. Sci. USA 84:1104-1106; 1987.
73. Juan, V.; Crain, C.; Wilson, C. Evidence for evolutionarily conserved secondary structure in the H19 tumour suppressor RNA. Nucleic Acids. Res. 28:1221-1227; 2000.
74. Runge, S.; Nielsen, F. C.; Nielsen, J.; Lykke-Andersen, J.; Wewer, U. M.; Christiansen, J. H19 RNA binds four molecules of insulinlike growth factor II mRNA-binding protein. J. Biol. Chem. 275: 29562-29569; 2000.
75. Blin-Wakkach, C.; Lezot, F.; Ghoul-Mazgar, S.; Hotton, D.; Monteiro, S.; Teillaud, C.; Pibouin, L.; Orestes-Cardoso, S.; Papagerakis, P.; Macdougall, M.; Robert, B.; Berdal, A. Endogenous Msx1 antisense transcript: In vivo and in vitro evidences, structure, and potential involvement in skeleton development in mammals. Proc. Natl. Acad. Sci. USA 98:7336-7341; 2001.
76. Nemes, J. P.; Benzow, K. A.; Koob, M. D. The SCA8 transcript is an antisense RNA to a brain-specific transcript encoding a novel actin-binding protein (KLHL1). Hum. Mol. Gen. 9:1543-1551; 2000.
77. Dhruba, J.; SenGupta Zhang, B.; Kraemer, B.; Pochart, P.; Fields, S.; Wickens, M. A three-hybrid system to detect RNA-protein interactions in vivo. Proc. Natl. Acad. Sci. USA 93:8496-8501; 1996.
78. Ohlsson, R.; Renkawitz, R.; Lobanenkov, V. CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet. 17:520-527; 2001.
79. Costello, J. F.; Fruhwald, M. C.; Smiraglia, D. J.; Rush, L. J.; Robertson, G. P.; Gao, X.; Wright, F. A.; Feramisco, J. D.; Peltomaki, P.; Lang, J. C.; Schuller, D. E.; Yu, L.; Bloomfield, C. D.; Caligiuri, M. A.; Yates, A.; Nishikawa, R.; Huang, H. J. S.; Petrelli, N. J.; Zhang, X. L.; O'Dorisio, M. S.; Held, W. A.; Cavenee, W. K.; Plass, C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 24: 132-138; 2000.
80. Huang, T. H.; Perry, M. R.; Laux, D. E. Methylation profiling of CpG islands in human breast cancer cells. Hum. Mol. Genet. 8: 459-470; 1999.
81. Gardiner-Garden, M.; Frommer, M. CpG islands in vertebrate genomes. J. Mol. Biol. 196:261-282; 1987.